DOI: 10.12890/2026_007398
Iatrogenic hypercalcemia in a patient with type 2 diabetes and chronic kidney disease
Authors
majamacko@yahoo.com
Keywords
Iatrogenic hypercalcemia, cardiovascular-kidney-metabolic syndromeAbstract
Introduction: The introduction of glucagon-like peptide-1 receptor agonists (GLP-1 RA) and non-steroidal mineralocorticoid receptor antagonists (nsMRA) has significantly improved outcomes in patients with type 2 diabetes, obesity and chronic kidney disease (CKD). However, the increasing use of combination therapies may result in previously unrecognized adverse drug interactions.
Case description: We report the case of a 59-year-old man with obesity, type 2 diabetes, CKD stage 3b, albuminuria and established cardiovascular disease receiving optimized treatment with renin–angiotensin–aldosterone system blockade, sodium-glucose cotransporter-2 inhibition, semaglutide and finerenone. Mild finerenone-associated hyperkalaemia was treated with calcium polystyrene sulfonate. Several weeks later, the patient developed symptomatic severe non-parathyroid hormone-mediated hypercalcemia accompanied by acute kidney injury, fatigue, muscle weakness, constipation, polyuria and polydipsia. Extensive investigations excluded solid and haematological malignancy, granulomatous disease and endocrine disorders. Hypercalcemia was attributed to increased calcium absorption from calcium polystyrene sulfonate, likely facilitated by prolonged gastrointestinal transit secondary to semaglutide-induced constipation. Treatment consisted of withdrawal of the offending medications, aggressive intravenous hydration, loop diuretics and a reduced dose of intravenous zoledronic acid, resulting in normalization of serum calcium and recovery to baseline kidney function. Semaglutide and finerenone were subsequently reintroduced without recurrence of hyperkalaemia or hypercalcemia, eliminating the need for potassium binders.
Conclusion: This case highlights a previously unreported mechanism of iatrogenic hypercalcemia resulting from the interaction between contemporary cardio-renal-metabolic therapies and underscores the importance of careful monitoring for unexpected adverse effects when combining newer agents with established treatments.
References
- Singh A, Kesani H, Verma S, Saleh TM, Rai M. Cardio-Renal Metabolic Syndrome: An Integrated Approach to Prevention and Management. Cureus. 2025;17(10):e94134. doi: 10.7759/cureus.94134.
- Morales J, Palmer BF. Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review. Postgrad Med. 2024;136(2):111-119. doi: 10.1080/00325481.2024.2316572.
- Rastogi A, Chertow GM, Collins A, Kelepouris E, Kotzker W, Middleton JP, et al. Utilization of Potassium Binders for the Management of Hyperkalemia in Chronic Kidney Disease: A Position Statement by US Nephrologists. Adv Kidney Dis Health. 2024;31(6):514-522. doi: 10.1053/j.akdh.2024.08.003.
- Arroyo D, Panizo N, García de Vinuesa S, Goicoechea M, Verdalles U, Luño J. Hypercalcemia as a side effect of potassium binding agents. Nefrologia. 2012;32(5):655-8. English, Spanish. doi: 10.3265/Nefrologia.pre2012.Jun.11500.
- Wang X, Chen D, Song X, Wang J, Zhang H. Efficacy and safety of calcium polystyrene sulfonate in patients with hyperkalemia and stage 3-5 non-dialysis chronic kidney disease: a single-center randomized controlled trial. J Int Med Res. 2023;51(4):3000605231167516. doi: 10.1177/03000605231167516.
- Long JJ, Sahi SS, Lemke AI, Na J, Garcia Valencia OA, Budhiraja P, et al. The Use of Semaglutide in Patients With Renal Failure-A Retrospective Cohort Study. Endocr Pract. 2024;30(10):963-969. doi: 10.1016/j.eprac.2024.07.008.
- Calabrese V, Messina RM, Cernaro V, Farina A, Di Pietro Y, Gembillo G, et al. Hypercalcemia: a practice overview of its diagnosis and causes. Kidney Dial. 2025;5(1):7. doi:10.3390/kidneydial5010007.
- Asogan H, Al Salmi I, Jha DK, Al Rahbi F, Hannawi S. Beta-2-microglobulin level increases with advanced CKD stages: the implications and significance. World J Med Oncol. 2020;1(1). doi:10.52338/wjoncgy.2020.1003.
- Argyropoulos CP, Chen SS, Ng YH, Roumelioti ME, Shaffi K, Singh PP, et al. Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases. Front Med (Lausanne). 2017;4:73. doi: 10.3389/fmed.2017.00073.
- Henry N, Hildebrand S, Cunningham J. Management of osteoporosis in chronic kidney disease. Clin Kidney J. 2025;18(10):sfaf228. doi: 10.1093/ckj/sfaf228.
